<DOC>
	<DOCNO>NCT02003742</DOCNO>
	<brief_summary>The purpose international , multicenter , randomise , single-blind , parallel group , Phase III study demonstrate single transrectal ultrasound ( TRUS ) -guided intraprostatic injection NX-1207 provide long lasting therapeutic improvement Lower Urinary Tract Symptoms ( LUTS ) associate Benign Prostatic Hyperplasia ( BPH ) patient adequately control medical therapy α-blockers , assess change baseline International Prostate Symptom Score ( IPSS ) total score .</brief_summary>
	<brief_title>Efficacy Safety Single TRUS-guided Intraprostatic Injection NX-1207 Patients With LUTS Due BPH</brief_title>
	<detailed_description />
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<criteria>Signed informed consent ; Age 45 older ; Medical history LUTS/BPH Use market αblocker LUTS/BPH last 8 week ; LUTS/BPH adequately control medical therapy αblockers ; Presence moderatesevere LUTS ( IPSS ≥ 15 ) screen baseline ( 4 week runin period tamsulosin 0.4 mg QD ) ; Prostate Volume ≥ 30 mL ≤ 70 mL ( assessed TRUS ) ; Qmax &lt; 15 mL/sec base minimum void 125 mL ; Agree use approve experimental BPH overactive bladder ( OAB ) medication anytime core study ; Agree perform followup visit even case oral treatment discontinuation study end ; Satisfactory compliance runin medication Visit 2 ( baseline ) . Previous surgical invasive prostate treatment TURP , TUMT , TUNA , laser minimally invasive treatment ; Acute chronic prostatitis suspect prostatitis include chronic pain , intermittent pain abnormal sensation penis , testis , anal pelvic area past 12 month ; PSA ≥ 10 ng/mL . In case PSA 4.0 10.0 ng/mL , prostate cancer must rule satisfaction clinical Investigator historical biopsy ; Prostate bladder cancer , history pelvic irradiation ; Active recurrent urinary tract infection ( 1 episode last 12 month ) ; History neurogenic bladder LUTS secondary neurologic disease ; Use selfcatheterization urinary retention ; Postvoid residual urine volume &gt; 200 mL ; Haematuria appropriately evaluate determine safe subject participation ; Renal insufficiency ( serum creatinine &gt; 2.0 mg/dL ) ; Liver insufficiency ( liver function test [ LFTs ] &gt; 2x upper limit normal [ ULN ] ) ; Poorly control diabetes ( type 1 type 2 ) , determine HbA1c &gt; 6 % and/or glycosuria ; Any bleed disorder haemophilia , clot factor ( ) deficiency bleed diathesis ; Immunosuppressive disorder , Human Immunodeficiency ( HIV ) Virus , Acquired Immune Deficiency Syndrome ( AIDS ) , lymphoproliferative disorder ; Acute chronic intestinal disease , ulcerative colitis , Crohn 's disease , acute gastroenteritis runin period ; acute painful perianal disorder ; Unstable cardiovascular cerebrovascular disease ( include acute myocardial infarction , unstable angina pectoris , bypass , Percutaneous Transluminal Coronary Angioplasty ( PTCA ) , congestive heart failure NYHA Class IIIIV , stroke , transient ischemic attack episode cardiac arrhythmia require treatment last 6 month ) ; Any condition would interfere subject 's ability provide inform consent , comply study instruction , might confound interpretation study result , dementia , psychosis , manic depressive disorder , posttraumatic stress disorder , stroke , Alzheimer 's , depression , psychiatric illness , history current evidence drug alcohol abuse within last 12 month etc . ; Participation study investigational drug device within previous 6 month ; Hypersensitivity contraindication tamsulosin use ; Use prohibit medication could endanger subject perform intraprostatic injection could interfere evaluation study parameter ; Men plan child future ; Any condition may interfere study endanger subject .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>LUTS</keyword>
	<keyword>BPH</keyword>
</DOC>